万孚生物拟最高6000万回购用于股权激励加码创新三年半研发投入累达15.13亿

Core Viewpoint - Wanfu Bio plans to repurchase shares to boost investor confidence, with a total repurchase amount between 30 million and 60 million yuan, aiming to enhance long-term incentive mechanisms and promote business growth [2][3]. Group 1: Share Repurchase Announcement - The company announced a share repurchase plan using its own funds, with a total amount not less than 30 million yuan and not exceeding 60 million yuan, at a maximum price of 34.66 yuan per share [2]. - The estimated number of shares to be repurchased ranges from approximately 865,600 to 1,731,100, accounting for about 0.18% to 0.37% of the total share capital [2]. - The repurchase period is set for six months from the date of the board's approval of the final repurchase plan [2]. Group 2: Financial Performance - In the first half of 2025, the company faced significant challenges in the in vitro diagnostic industry, with revenue of 1.246 billion yuan, a year-on-year decrease of 20.92%, and a net profit of 189 million yuan, down 46.82% year-on-year [3]. - The company has increased its R&D investment as a core strategy to address industry pressures, with cumulative R&D expenditures reaching 1.513 billion yuan from 2022 to the first half of 2025 [3][4]. - R&D investment as a percentage of total revenue has shown an upward trend, with ratios of 7.87%, 15.26%, 14.3%, and 16.53% for the respective periods [3]. Group 3: Technological Advancements - The company achieved breakthroughs in several strategic areas, particularly in the chemiluminescence sector, launching the LA-6000 laboratory intelligent assembly line to expand terminal coverage [4]. - The company has optimized product performance for single-use chemiluminescence platforms, enhancing reagent sensitivity and stability to meet the demand for immediate and miniaturized testing solutions [4]. - As of June 30, 2025, the company holds 490 valid patents, including 141 invention patents, 264 utility model patents, and 85 design patents [4].